AstraZeneca Statistics
AstraZeneca (ZEG) Stock Statistics & Valuation Metrics
Total Valuation
AstraZeneca has a market cap or net worth of EUR 257.45B. The enterprise value is EUR 211.22B.
- Market Cap
- EUR 257.45B
- Enterprise Value
- EUR 211.22B
Share Statistics
AstraZeneca has 1,551,065,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,551,065,200
- Owned by Insiders
- 0.04%
- Owned by Institutions
- 36.79%
Financial Efficiency
AstraZeneca’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 13.04%.
- Return on Equity (ROE)
- 0.21
- Return on Assets (ROA)
- 0.09
- Return on Invested Capital (ROIC)
- 13.04%
- Return on Capital Employed (ROCE)
- 0.16
- Revenue Per Employee
- 611.23K
- Profits Per Employee
- 106.40K
- Employee Count
- 96,100
- Asset Turnover
- 0.51
- Inventory Turnover
- 1.62
Valuation Ratios
The current PE Ratio of AstraZeneca is 26.03. AstraZeneca’s PEG ratio is 1.57.
- PE Ratio
- 26.03
- PS Ratio
- 4.60
- PB Ratio
- 5.59
- Price to FCF
- 31.58
- Price to Operating Cash Flow
- 21.51
- PEG Ratio
- 1.57
Income Statement
In the last 12 months, AstraZeneca had revenue of 58.74B and earned 10.22B in profits. Earnings per share was 6.60.
- Revenue
- 58.74B
- Gross Profit
- 48.11B
- Operating Income
- 13.74B
- Pretax Income
- 12.40B
- Net Income
- 10.22B
- EBITDA
- 19.83B
- Earnings Per Share (EPS)
- 6.60
Cash Flow
In the last 12 months, operating cash flow was 13.36B and capital expenditures -4.26B, giving a free cash flow of 9.10B billion.
- Operating Cash Flow
- 13.36B
- Free Cash Flow
- 9.10B
- Free Cash Flow per Share
- 5.87
Dividends & Yields
AstraZeneca pays an annual dividend of EUR 0.88, resulting in a dividend yield of 1.71%
- Dividend Per Share
- EUR 0.88
- Dividend Yield
- 1.71%
- Payout Ratio
- 8.44%
- Free Cash Flow Yield
- 3.14%
- Earnings Yield
- 3.81%
Stock Price Statistics
- Beta
- 0.61
- 52-Week Price Change
- 11.35%
- 50-Day Moving Average
- 147.51
- 200-Day Moving Average
- 155.76
- Relative Strength Index (RSI)
- 64.31
- Average Volume (3m)
- 1,078
Important Dates
AstraZeneca upcoming earnings date is Feb 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 30, 2026
- Next Earnings Date
- Feb 11, 2027
- Ex-Dividend Date
- Aug 07, 2025
Financial Position
AstraZeneca as a current ratio of 0.94, with Debt / Equity ratio of 60.87%
- Current Ratio
- 0.94
- Quick Ratio
- 0.72
- Debt to Market Cap
- 0.10
- Net Debt to EBITDA
- 1.21
- Interest Coverage Ratio
- 8.11
Taxes
In the past 12 months, AstraZeneca has paid 2.17B in taxes.
- Income Tax
- 2.17B
- Effective Tax Rate
- 0.17
Enterprise Valuation
AstraZeneca EV to EBITDA ratio is 14.78, with an EV/FCF ratio of 34.67.
- EV to Sales
- 5.05
- EV to EBITDA
- 14.78
- EV to Free Cash Flow
- 34.67
- EV to Operating Cash Flow
- 23.61
Balance Sheet
AstraZeneca has EUR 8.11B in cash and marketable securities with EUR 33.97B in debt, giving a net cash position of -EUR 25.86B billion.
- Cash & Marketable Securities
- EUR 8.11B
- Total Debt
- EUR 33.97B
- Net Cash
- -EUR 25.86B
- Net Cash Per Share
- -EUR 16.67
- Tangible Book Value Per Share
- -EUR 4.80
Margins
Gross margin is 77.59%, with operating margin of 23.60%, and net profit margin of 17.69%.
- Gross Margin
- 77.59%
- Operating Margin
- 23.60%
- Pretax Margin
- 21.33%
- Net Profit Margin
- 17.69%
- EBITDA Margin
- 34.21%
- EBIT Margin
- 23.91%
Analyst Forecast
The average price target for AstraZeneca is EUR 194.22, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 194.22
- Price Target Upside
- 16.79% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 17
- Revenue Growth Forecast
- 2.06%
- EPS Growth Forecast
- 11.63%
Scores
- Smart Score
- 10
- AI Score
- ―
